Conference Track

Clinical Updates in HBV Treatment

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Long-term HBV DNA Suppression Achieved With Entecavir in Nucleoside-Naive HBeAg-Positive Chronic Hepatitis B Patients
HBV Antiviral Resistance Patterns in HBV Mirror Prescription Trends
Tenofovir Therapy Associated With Significantly Greater Efficacy and Comparable Safety vs Adefovir in HBeAg-Negative HBV Patients
Tenofovir Therapy Associated With Significantly Greater Efficacy and Comparable Safety vs Adefovir in HBeAg-Positive HBV Patients
HBV DNA Level and Subgenotype as HCC Predictors in Chronic Hepatitis B Patients
High HBsAg Seroconversion Rate Observed Among HBeAg-Positive Patients Who Achieved SVR to Standard Interferon Associated With Excellent Histologic Outcomes
Trajectory Modeling of REVEAL HBV DNA Subgroups Demonstrates That Increased Levels Over Time Associated With Increased HCC Risk
Tenofovir Demonstrates Significant Anti-HBV Activity in Adefovir-Resistant Chronic Hepatitis B Patients
Significantly Increased Risk of HCC in Chronic Hepatitis B HBsAg-Positive Patients With HBV DNA < 10⁴ copies/mL vs HBsAg-Seronegative Patients
Tenofovir Significantly Decreases HBV DNA in Lamivudine- and Adefovir-Experienced Patients With No Adefovir Resistance
Entecavir Treatment in HBV Patients Achieves HBV DNA Reduction but Not HBV DNA Undetectability With Limited Response to Adefovir
Approximately One Half of HBeAg-Positive Initial Nonresponders to Entecavir Achieve Undetectable HBV DNA With Extended Treatment
GLOBE Study: Baseline and On-Treatment Predictors of Optimal Virologic Response to Telbivudine Identified for HBV Patients
Correlation Between HBV DNA and Liver Disease Progression Demonstrated in Chronic HBV Patients From Northeastern Greece During 12-Year Observational Study
No Survival Benefit Found With Nucleoside Analogue Use in HBV-Related Acute Liver Failure Patients

Expert Analysis

Clinical Updates in HBV Treatment

Faculty:

Emmet B. Keeffe, MD, MACP
Fred Poordad, MD
Paul Martin, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies on HBV and its associated complications, including hepatocellular carcinoma
Discuss results of clinical studies of approved and investigational treatments for chronic HBV
Recount strategies for managing patients with drug-resistant HBV

CREDIT INFORMATION

Release Date: January 09, 2008

Expiration Date: January 08, 2009

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.